# Screening survivors: where the UK, American and European answers differ

Source: https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/  
OnCo record `rejuv-second-screening-after-treatment-compared` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Three systems have built screening for survivors and they do not agree. England runs an organised programme with fixed ages and automatic referral; the United States issues a guideline and leaves the arranging to the patient; the Netherlands runs a national survivorship clinic network. They differ on when to start and whom to include.

## Summary

Breast, after chest radiotherapy: the clearest disagreement. The American Cancer Society recommends annual breast MRI plus mammogram for women at high risk "typically starting at age 30", and lists among that group women who "had radiation therapy to the chest before they were 30 years old". England screens women who had radiotherapy to breast tissue between 10 and under 36, starts at 25 for those irradiated between 10 and under 20 and at 30 for those irradiated between 20 and under 36, and in both cases not before eight years after the first irradiation. So the two differ on three things at once: the upper age of exposure that qualifies (30 in the American guideline, under 36 in England), the age at which screening begins (30 against 25 or 30), and whether a latency rule applies (England yes, the American guideline no). A woman irradiated at 33 qualifies in England and does not meet the American criterion as written.

How the arranging differs, which matters more than the ages. England identifies eligible women centrally by cross-matching cancer registry and radiotherapy records through BARD and sends a referral to the local screening service. The American guideline states that "the decision to follow this guideline should be made with a woman's healthcare providers, taking into account her personal circumstances and preferences", which puts the burden of knowing the guideline exists on the woman and her clinician. An organised programme catches people who do not know they are at risk; a guideline does not.

The Dutch model, and what it found about itself. The BETER consortium runs a nationwide survivorship care programme for survivors of Hodgkin lymphoma from five years after diagnosis, offering risk-based screening for and treatment of late effects. The INSIGHT study compared survivors who received BETER care from 2013 to 2016 (n = 251) with matched survivors who did not receive survivorship care until 2019 to 2024 (n = 119), at a median of about 25 years from diagnosis. Health-related quality of life showed no significant differences between the groups, and overall matched that of the Dutch general population. Knowledge of late effects "was suboptimal in both groups, and distress levels were similarly low". Eighty per cent of survivors perceived BETER care as beneficial, "with most individuals stating that increased knowledge outweighed potential worries". A national programme that publishes a null result about its own effect on quality of life is doing the thing this site asks of a source.

Thyroid: a guideline that declines to recommend. The International Late Effects of Childhood Cancer Guideline Harmonization Group with PanCareSurFup compared thyroid ultrasound against neck palpation for survivors of childhood, adolescent and young adult cancer and found that "neither was shown to be superior", producing a decision aid and a recommendation for shared decision making instead of a protocol.

Bowel: a recommendation for one group and silence for the other. Colonoscopy surveillance after abdominal or pelvic radiotherapy is part of the long-term follow-up guidelines for people treated as children. For adults treated as adults, no organised colonoscopy programme exists on this basis in the United Kingdom, the United States or Europe, and the national bowel screening programmes invite survivors on the same terms as everyone else.

Lung and skin: no programme anywhere. Lung cancer screening is offered on smoking history, not on treatment history, even though measured second-primary lung cancer rates in survivors of some head and neck cancers exceed the rate in the control arm of the trial that established screening works. No country screens survivors' skin.

What is shared. All three systems agree that the person needs a written treatment summary listing what they were given, at what dose and to what part of the body, and that without it none of the above can be applied. The corpus record on survivorship care plans covers what that document should contain.

What nobody has shown. No randomised trial has shown that any survivorship screening programme reduces death from a second cancer. The breast programme rests on the size of the measured risk and on the general evidence that MRI finds breast cancer earlier in high-risk women, not on a trial in irradiated survivors, and there will not be one. That is the honest basis of a programme worth being enrolled in.

## Fields

- Kind: Term
- Last checked: 2026-10-02
- Also known as: Survivorship screening guidelines; Late effects surveillance; BETER consortium; Risk-based survivorship care
- Tags: rejuvenation; survivorship; second-cancers; screening; survivorship

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cancer_screening
- American Cancer Society: Recommendations for the early detection of breast cancer: https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
- Saslow et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography (CA Cancer J Clin 2007): https://doi.org/10.3322/canjclin.57.2.75
- NHS England: Eligibility criteria and screening protocols for women at very high risk of breast cancer (updated 18 November 2025): https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/tests-and-frequency-of-testing-for-women-at-very-high-risk--2
- Lammers et al., Influence of survivorship care on health-related quality of life, knowledge of late effects, and distress levels among long-term Hodgkin lymphoma survivors, the INSIGHT study (Cancer Med 2025): https://doi.org/10.1002/cam4.71113
- Clement et al., Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium (Cancer Treat Rev 2018): https://doi.org/10.1016/j.ctrv.2017.11.005
- Children's Oncology Group: survivorship resources and long-term follow-up guidelines: https://childrensoncologygroup.org/survivorship

## Connected records

- terms: [After Hodgkin lymphoma: the late effects, and the screening that follows them](https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/), [Age, smoking and inherited predisposition: what the treatment risk is added to](https://onco.cc/terms/rejuv-second-age-smoking-and-inherited-risk/), [Bowel cancer after abdominal and pelvic radiotherapy](https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/), [Breast cancer after chest radiotherapy given young](https://onco.cc/terms/second-primary-breast-after-chest-radiotherapy/), [Colonoscopy](https://onco.cc/terms/colonoscopy/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Sarcoma in the radiotherapy field, and angiosarcoma of the treated breast](https://onco.cc/terms/second-primary-sarcoma-in-the-treated-field/), [Second cancers after treatment: what the risk is, and what is done about it](https://onco.cc/terms/rejuv-second-cancers-overview/), [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/), [The UK very high risk breast screening protocol after chest radiotherapy](https://onco.cc/terms/rejuv-second-uk-very-high-risk-breast-screening/), [Thyroid cancer after neck radiotherapy, and whether to look for it](https://onco.cc/terms/second-primary-thyroid-after-neck-radiotherapy/), [What is not a second cancer: recurrence, metastasis and field cancerisation](https://onco.cc/terms/rejuv-second-what-is-not-a-second-cancer/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Low-dose CT lung screening](https://onco.cc/technologies/low-dose-ct-screening/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/), [MRI](https://onco.cc/technologies/mri/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [No randomised trial shows that any survivorship screening programme reduces death](https://onco.cc/bottlenecks/rejuv-agenda-screening-without-a-trial/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/)
- ideas: [Ask whether survivorship screening saves lives, using registry-based randomisation](https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-second-screening-after-treatment-compared.json